Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEAM: Adjuvant Exemestane vs Tamoxifen-Exemestane Sequence in Breast Cancer
NCT00279448Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jan 2002
- Primary completion
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of exemestane in breast cancer (2 arms), sponsored by Pfizer. Primary endpoint: Recurrence-Free Survival at 5 years. Started Jan 2002; status: completed.
02
Drugs
exemestane
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00279448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00279448.